logo
The three types of hunger – and how to stay fuller for longer

The three types of hunger – and how to stay fuller for longer

Yahoo5 days ago
For some people, eating a meal keeps them happily satiated until the next one, whereas for others, hunger is a far more complicated business. A couple of hours after eating, they're starving again and trying desperately not to succumb to the lure of the fridge or office vending machine.
But is what they're experiencing really physical hunger, also known as homeostatic hunger, or could it be fuelled by one of the other kinds? There is hedonic hunger – the drive to eat for pleasure, rather than out of a physiological need for energy and, one of the most persuasive, emotional hunger, where food serves as a form of self-soothing when negative feelings arise.
'Physical hunger, when your body needs refuelling, is just one type of hunger, but we don't necessarily talk about the other types as much – although we should, because understanding them can be important for our health,' says Dr Emily Leeming, a microbiome scientist at King's College London, dietician and author of Genius Gut.
Hedonic and emotional hunger are among the main culprits when it comes to weight gain. In fact, a broad new review of existing research found a significant positive link between hedonic hunger and food addiction, defined as symptoms similar to those in drug addiction, including cravings, tolerance and withdrawal effects – as well as to increased calorie intake and weight gain.
So which might you suffer from? Here's a science-backed guide to all three, understanding their triggers and learning how to beat them.
Physical hunger
That empty-stomach feeling, often accompanied by a growling sound, dip in energy and 'hanger' (hungry anger) – caused by cortisol and adrenaline rising as our blood sugars drop – is our body's way of signalling to the brain that we need food.
This drop in blood sugar and insulin levels, a few hours after eating, triggers the stomach to produce ghrelin, the hormone that stimulates appetite. But for some of us, our appetites seem to be in overdrive.
The reasons for this can be complex: some people seem to be less sensitive to the suppression of ghrelin that comes when the stomach encounters food, while for others, their brains could be less sensitive to leptin signals, which tell the brain to stop eating when we're full. For most people, however, focusing on what we eat can make a huge difference in managing our hunger. Eating too many refined white carbohydrates is one of the primary reasons many of us find ourselves reaching for sugary snacks between meals. 'With white or refined carbs, such as white bread, pasta and rice, most of their nutrients and fibre have been lost, so our bodies don't have to work hard to break them down,' says Laura Southern, the founder of London Food Therapy. 'That causes very high blood sugar spikes.'
These trigger an immediate release of insulin, causing blood glucose levels of fall, which then signals the release of hunger hormones to replenish them. Research from King's College London has shown that when blood sugar levels dipped below their baseline, people reported a 9 per cent increase in hunger and ate over 300 calories more that day than others whose blood sugar levels did not dip.
Tips to stop physical hunger pangs
Opting for unrefined carbs, such as oats, barley, rye and quinoa, will help keep blood sugar steady thanks to their higher fibre content.
'Ninety-three per cent of us are not getting the fibre we need, and we have a deficit of 35 to 40 per cent, which is a significant fibre gap,' says Dr Leeming. 'Fibre releases fullness hormones and it's quite bulky, so it gives that sense of fullness and satisfaction. It also feeds our gut microbiome, and there's early evidence that looking after the microbiome could potentially be involved in how tempting we find certain foods.'
She recommends starting the day with a protein-rich breakfast, such as yogurt or eggs, which has been proven to reduce food cravings and snacking later in the day, and adding fibre, such as fruit, vegetables or seeds.
Hedonic, or taste-hunger pangs
It's the smell of the freshly baked croissants we cannot resist on holiday; or that irresistible extra portion of the darkest, ooziest chocolate fondant cake for pudding, followed by the cheese board.
Eating for pleasure is one of our biggest drivers to consume more than we need. Food, quite rightly, is a sensory joy – and we all experience a hankering for the fattier, sugary treats, with temptation and advertising bombarding us from all corners. But for some, these cravings can spiral into persistent 'food noise' – intrusive thoughts about eating – or even develop into full-blown addiction. 'When we eat foods we find particularly appealing, our brain releases dopamine in its reward system,' explains Dr Anne-Laure Le Cunff, a neuroscientist at King's College London and founder of Ness Labs. 'This creates a sense of pleasure and reinforces the behaviour.'
Unlike homeostatic hunger, which we often mistake it for, hedonic hunger, aptly named after Hedone, the Greek goddess of pleasure, has no mechanism to signal when we should stop eating – hence, it's now seen by scientists as one of the biggest causes of obesity.
Tips to stop hedonic hunger pangs
But there are measures we can take to combat these cravings, and they aren't as simple as trying to avoid food for which we have a weakness. Dr Leeming says: 'Cutting out the food we crave won't necessarily solve the craving: one study showed that women who cut out chocolate had more food cravings, and when they did eat chocolate, they ate twice as much.'Instead, she suggests eating the food, but with something else. 'If it's chocolate, have it with some fruit and nuts, which combine protein, fibre and healthy fat, so you'll probably eat less chocolate and it's going to satisfy you more,' she says. Dark chocolate is a better choice, with research suggesting it could have a positive impact on blood sugar levels, reducing cravings for less nutritious foods later.
Maintaining a consistent eating pattern, including meal-times and portion sizes, is key to managing cravings, as a result of what's called the cold-hot empathy gap. In the cold state (meaning you're not starving hungry, and therefore feeling neutral, or 'cold' towards food) you're less likely to overestimate how hungry you'll be and overindulge – so this is the state to be in when you're planning meals. Getting enough sleep is also vital: research shows that just one night of poor sleep can significantly boost your ghrelin levels, making you snack more the next day. Eating spicy foods can help beat cravings, too. Capsaicin, the compound that makes peppers spicy, can suppress appetite and increase satiety. And don't skip bitter vegetables, such as dark leafy greens, since studies have shown they can trigger the release of appetite-control hormones in the gut and reduce our desire for sweet foods.
Emotional hunger
Research published last year by scientists at the University of California, Los Angeles in America found that women who perceive themselves to be lonely showed more brain activity in areas associated with food cravings, especially when shown pictures of high-calorie or sugary foods. The dopamine hit we experience when we eat these foods 'essentially teaches our brain that eating makes us feel better,' says Dr Le Cunff. For many people, this link between food and comfort is strong and dates way back to our childhoods. 'Over time, our brains learn to link eating with emotional relief,' says Dr Le Cunff. So when we're struggling emotionally, we're hard-wired to seek this kind of comfort, she explains. 'When we're stressed or feeling low, our brain's emotion centre, the amygdala, becomes more active and interacts with areas that control both hunger and reward-seeking behaviour.'Unfortunately, this can create unhealthy patterns, seeing us reach for food as comfort every time we experience negative emotions, then feeling guilty and ashamed – which can lead to yet more bingeing.
Recognising that emotional eating is a normal part of life is important, Dr Leeming advises: 'Don't beat yourself up – think about the bigger picture of what you're eating in a week.'
How to stop emotional hunger pangs
Taking note of the feelings which lead to unhealthy eating can help identify your triggers, which is the first step in breaking the pattern. Next time you experience one, Dr Le Cunff says: 'Many other activities can activate similar reward pathways, in healthier ways, and these alternatives can help us regulate our emotions without relying on food.'Try contacting a friend – even a text message can provide the social connection that increases bonding hormones such as oxytocin. Or go for a walk or dance around the kitchen to uplifting music. As little as 10 minutes in Zone Two, where your heart rate is around 125-140 BPM and you can talk but not hold a proper conversation, can increase dopamine levels. Yoga, meditation and deep breathing can help us cope with stress, as can creative pursuits such as painting, writing, or gardening – and they can all act as a diversionary tactic to take our mind off the craving until it passes.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

Yahoo

time25 minutes ago

  • Yahoo

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg® currently under review for potential approval by the EMA and MaaT033 currently in Phase 2b clinical evaluation Funding is part of the European Investment Bank (EIB)'s strategy to support biotech companies with cutting-edge expertise in therapeutic areas such as hemato-oncology Structured Debt financing from the EIB is another stepping stone in MaaT Pharma's multi-sourcing financing strategy LYON, France, July 28, 2025--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced that it has secured a €37.5 million, 4-tranche financing from the European Investment Bank (EIB). The financing will support the advancement of its late-stage hemato-oncology clinical programs including the lead-asset Xervyteg®, recently partnered with Clinigen in Europe, and currently under regulatory review by the European Medicines Agency (EMA) for the treatment of acute Graft-versus-Host Disease (aGvHD) and the second drug candidate, MaaT033, currently being evaluated in a Phase 2b randomized controlled trial in improving survival for patients receiving allogeneic stem cell transplants. With robust cGMP manufacturing, proprietary therapies, and a development platform, MaaT Pharma is a global leader in microbiome-based oncology, pioneering full-ecosystem therapies to improve survival in oncology. Since completing enrollment in the ARES trial for Xervyteg® (MaaT013) in October 2024, MaaT Pharma has steadily advanced its roadmap, reporting topline results in January 2025, submitting the Marketing Authorization Application with the European Medicines Agency in June 2025, and signing an exclusive agreement for marketing and distribution in Europe with Clinigen in July 2025. The €37.5 million financing from the EIB follows a rigorous due diligence process by the EIB and further confirms MaaT Pharma's innovation, strategic vision and operational maturity. This funding is part of a global financial strategy to support the Company's development that combines various non-dilutive and dilutive sources to best preserve shareholder value. Eric Soyer, Chief Financial Officer, MaaT Pharma, said: "We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma's growth on bringing the potential first microbiome-based therapy to market in Europe. Each operational and financing step strengthens our track record. Following the regulatory submission to the EMA for Xervyteg®(MaaT013) and our recent partnership with Clinigen for its commercialization, the EIB financing represents another step in reinforcing the Company's financial position. As previously announced, MaaT Pharma intends to fund its plans and development programs while preserving shareholder value in the best manner possible with a mix of non-dilutive and dilutive financial sources, and the recent announcements of both partnership financing with the Clinigen agreement and debt financing with the EIB agreement, are benchmarks to reflect that strategy." Summary of the main terms and conditions of the Loan and Warrants The loan would be available in four (4) tranches, respectively of €3.5 million for Tranche A, €6.0 million for Tranche B, €8.0 million for Tranche C, and €20.0 million for Tranche D, each tranche with Warrants attached. Disbursement of Tranches 2 to 4 are subject to operational and financing conditions. All Tranches are redeemable after a grace period of 4 years from the date of drawing, with reimbursement over a period of 2 years (Tranche A, B and C, i.e. a maturity of 6 years) to 4 years (Tranche D, i.e. a maturity of 8 years). Each tranche will bear interests at 7%, it being provided that some interests will be deferred and paid at maturity and for Tranche C and Tranche D part of the interest will be paid quarterly. MaaT Pharma will issue warrants to the benefit of EIB at the time of (and subject to) disbursement of each tranche in a number depending, for each relevant tranche, on the amount of the relevant tranche and the average price per share paid by investors in the context of equity injection made prior to disbursement of the relevant tranche (except for tranche A where the average price per share over the last trading days preceding the date of execution of the financing agreement). Each warrant will give right to subscribe to one share at a price per warrant equal to 99% of the average price over a period of 5 trading days preceding the issuance of each Warrant. The Warrants may be exercised at any time following maturity of Tranche A. The Warrants will have a 20-year term. EIB and MaaT Pharma have also agreed on (i) a put option to the benefit of EIB under which MaaT Pharma undertook to acquire from EIB all or part of the Warrants upon occurrence of certain events and (ii) a call option to the benefit of MaaT Pharma under which EIB undertook to sell all its Warrants, upon occurrence of a public tender offer over the securities issued by MaaT Pharma. The Warrants are not transferable, except to affiliates of EIB or except in case of occurrence of certain events (including maturity date of Tranche D). In case of transfer of Warrants to third party, MaaT Pharma shall benefit from a preemptive right to acquire the Warrants first. MaaT Pharma was assisted in this transaction by Mr. Eric Briole and by Van Lanschot Kempen as Financial Advisors and McDermott Will & Emery as Legal Advisor. About EIB The European Investment Bank (EIB), whose shareholders are the Member States of the European Union (EU), is the EU's long-term financing institution. Across eight major priorities, we support investments in climate action and the environment, digital transition and technological innovation, security and defense, cohesion, agriculture and the bioeconomy, social infrastructure, capital markets union, and a stronger Europe in a more peaceful and prosperous world. In 2024, the EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing in support of more than 900 projects in Europe and worldwide. In France, the EIB Group signed over a hundred operations in 2024 for a total amount of €12.6 billion. Nearly 60% of the EIB Group's annual financing supports projects contributing to climate change mitigation and adaptation, as well as the creation of a healthier environment. About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. View source version on Contacts EIB Andrea Morawski, mobile: +352 691 284 349Website: – Press Office: press@ MaaT Pharma – Investor Relations Guilhaume DEBROAS, of Investor Relations+33 6 16 48 92 50invest@ MaaT Pharma – Media Relations Pauline RICHAUDSenior PR & Corporate Communications Manager+33 6 14 06 45 92media@ Catalytic Agency – U.S. Media Relations Heather SheaMedia relations for MaaT Pharma+1

Resident doctors strike in the face of a tiring public
Resident doctors strike in the face of a tiring public

Yahoo

time25 minutes ago

  • Yahoo

Resident doctors strike in the face of a tiring public

Up to 50,000 NHS resident doctors are currently on strike over pay, their twelfth walkout since March 2023. So what? This month Labour announced an ambitious plan meant to revive a health service that is on its knees. Any detail from that has now been overtaken by a downing of tools that will severely disrupt medical treatments; could encourage similar action by nurses; and may lead to patient deaths. Here we go again. Ending resident doctor strikes was one of the health secretary Wes Streeting's first priorities. Last year he struck a deal with the British Medical Association to increase pay by 22 per cent. This was a temporary boost, since it only applied to 2023-25 salaries. For 2025-26, the rise was 5.4 per cent. Not good enough. This is better than the 3.6 per cent pay rise awarded to nurses in June 2025. But the BMA wants full 'pay restoration'. It says the salaries of resident doctors, who are still in training, are 21 per cent lower in real terms than in 2008 because of inflation. Damned statistics. The BMA uses the Retail Price Index (RPI) to reach this number. The government uses another measure, the Consumer Price Index (CPI). This is the official metric used to calculate changes to the cost of living, based on a basket of consumer goods. If CPI is used, pay has only fallen by 4.7 per cent since 2008, according to the Nuffield Trust. Hang on. The BMA's insistence on using RPI is based, in part, on the fact that the government uses it to calculate rail fares and interest payments on student debt. The latter is particularly relevant. Although they earn a relatively high salary after 5 years in training (£61,825 a year, excluding compulsory overtime), doctors emerge from five years of medical school owing as much as £100,000. Ouch. That's nearly double the average debt pile of British graduates. Unlike many other professionals, medical trainees also spend thousands of pounds on exam fees and courses. Another thing. Pay isn't the only grievance, with resident doctors also complaining about a shortage of speciality training posts, which means many get stuck on the middle rungs of the career ladder; an arcane placement system that requires them to move around the country at a few months' notice; and gruelling hours and stressful working conditions. Cash-strapped. This time round, the health secretary is less sympathetic and says there is no more money for pay rises. Last year's increases ate up more than half of the extra £10.4 billion given to the NHS. Streeting would rather be getting on with plans to revamp the health system. These are centred around shifting care from hospitals to the community; making better use of digital tech; and preventing sickness in the first place. Shifting opinions. The public seems to be on his side. In 2024, more than half of Brits supported strike action by trainee doctors. This has fallen to 32 per cent. The head of the Royal College of Nursing has said it is 'grotesque' to hand doctors bigger increases than nurses. Negotiations. In an unsuccessful bid to avert the strikes, Streeting made several last-minute offers, including accelerating doctors' training so they progress through the pay scales faster; giving them part of their pensions upfront; and subsidising exam fees. The toll. Previous rounds of strikes led to the cancellation of 1.5 million planned appointments, as well as five deaths. Labour is eager to avert more cancellations, having made much of bringing down waiting lists. NHS England has not postponed scheduled non-urgent care. What's more… The BMA has criticised this decision, saying it puts lives at risk. Critics have pinned the responsibility on them, saying they chose to strike. Either way, patients will suffer.

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

Yahoo

timean hour ago

  • Yahoo

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros' mission to develop treatments for the unmet need of patients with rare lysosomal storage disorders The news follows the company's recent successful €132M Series B financing, aimed at supporting the rapid development of nizubaglustat and the expansion of Azafaros' pipeline to other indications LEIDEN, Netherlands, July 28, 2025--(BUSINESS WIRE)--Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. "The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy." About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store